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Introduction
Juvenile idiopathic arthritis (JIA) is a chronic inflammatory
disease of childhood. It is associated with decreased bone
mineral density (BMD), as result of disturbance of bone
metabolism which develops gradually and progressively
influenced by many factors, presumably by disease severity.
Objectives
To examine bone mineral status in patients with JIA
after 12 months of treatment with etanercept (ETN).
Methods
In prospective study of 63 polyarticular JIA pts (46 F, 17
M), median age 15 yrs. Treated with ETN 0,4 mg/kg/2×
week. BMD and bone mineral content (BMC) by dual x-
ray absorptiometry on the lumbar spine (L2-L4) were
assessed. For statistical analysis Z score and bmdvol were
taken as well. ACR pedi 50 criteria (physician global assess-
ment-PGA, parent’s/patient’s global assessment, No of
joints with limited range of motion-LOM, No of joints
with active arthritis, functional ability assessment using
CHAQ-Serbian version and ESR) were done at the baseline
and one year later.
Results
We found significant improvement in all six variables
represented disease activity, after 12 mo of treatment
with ETN (PGA 80%, parent’s/patient’s global assessment
56%, No of LOM joints 68%, No joints with active arthri-
tis 80%, functional ability 60%, ESR 37% (p < 0.001). At
the last visit 54 (85,7%) pts met the ACR pedi 50 criteria,
assigned as responders (Group I), while 9 (14,3%) were
nonresponders (Group II). After one year of treatment
with ETN it was shown high statistically significant incre-
ment in all osteodensitometry variables (p < 0.001).
Annual enhancement for BMC was 11.7%, for BMD
6.1%, for bmdvol 3.4% for whole group. Z score improved
from -1.03 to -0.81 SD at the last visit. Comparing
annually difference of BMD between responders and
nonresponders we found statistically significant improve-
ment in the first group (6.78% vs. 2.23%, p < 0.02) as well
bmdvol (4.31% vs. -0.87%, p < 0.013).
Conclusion
Our results confirmed significant suppression of disease
activity and improvement of bone mineral status in chil-
dren with JIA after a year of treatment with ETN. Thus
reasonable therapeutic approach in preventing osteoporo-
sis in the later life are the new therapeutic options as ETN
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